- Home
- IREN vs CGON Comparison
IREN vs CGON Comparison
Compare IREN & CGON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IREN
- CGON
- Stock Information
- Founded
- IREN 2018
- CGON 2010
- Country
- IREN Australia
- CGON United States
- Employees
- IREN N/A
- CGON N/A
- Industry
- IREN EDP Services
- CGON
- Sector
- IREN Technology
- CGON
- Exchange
- IREN Nasdaq
- CGON NYSE
- Market Cap
- IREN 1.4B
- CGON 1.3B
- IPO Year
- IREN 2021
- CGON 2024
- Fundamental
- Price
- IREN $7.04
- CGON $23.74
- Analyst Decision
- IREN Strong Buy
- CGON Strong Buy
- Analyst Count
- IREN 11
- CGON 11
- Target Price
- IREN $19.30
- CGON $62.90
- AVG Volume (30 Days)
- IREN 13.1M
- CGON 2.0M
- Earning Date
- IREN 05-14-2025
- CGON 05-20-2025
- Dividend Yield
- IREN N/A
- CGON N/A
- EPS Growth
- IREN N/A
- CGON N/A
- EPS
- IREN N/A
- CGON N/A
- Revenue
- IREN $285,765,000.00
- CGON $1,139,000.00
- Revenue This Year
- IREN $183.61
- CGON N/A
- Revenue Next Year
- IREN $80.31
- CGON $16,237.24
- P/E Ratio
- IREN N/A
- CGON N/A
- Revenue Growth
- IREN 133.25
- CGON 461.08
- 52 Week Low
- IREN $4.65
- CGON $14.80
- 52 Week High
- IREN $15.92
- CGON $40.47
- Technical
- Relative Strength Index (RSI)
- IREN 58.89
- CGON 49.91
- Support Level
- IREN $6.01
- CGON $21.00
- Resistance Level
- IREN $6.63
- CGON $30.23
- Average True Range (ATR)
- IREN 0.38
- CGON 2.33
- MACD
- IREN 0.17
- CGON 0.06
- Stochastic Oscillator
- IREN 87.04
- CGON 30.94
About IREN Iris Energy Limited
IREN Ltd is engaged in data center business powering the future of Bitcoin, AI and beyond utilizing renewable energy.
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.